Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease
José Marco‐Contelles, Carolina Rodríguez, Antonio G. Garcı́a
Abstract
José Marco‐Contelles, Carolina Rodríguez, Antonio G. Garcı́a
Abstract
(-)-Galantamine, an alkaloid isolated from the Caucasian snow-drop (Galanthus woronowii), is a selective, reversible and competitive inhibitor of acetylcholinesterase (AChE), as well as an allosteric modulator of the neural nicotinic receptor for acetylcholine. Galantamine is the most recently approved AChE inhibitor for the symptomatic treatment of Alzheimer’s disease. Because of the limited supplies from natural sources, several total syntheses have been reported to produce this drug. Galantamine has attracted both the interest of organic chemists and pharmacologists in a collaborative effort directed to design, prepare and evaluate more biologically active molecules for the treatment of Alzheimer’s disease. In this review the recent patent literature will be reviewed, showing the most important chemical and/or biochemical advances of the chemistry and biology of galantamine.
OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
(-)-Galantamine, an alkaloid isolated from the Caucasian snow-drop (Galanthus woronowii), is a selective, reversible and competitive inhibitor of acetylcholinesterase (AChE), as well as an allosteric modulator of the neural nicotinic receptor for acetylcholine. Galantamine is the most recently approved AChE inhibitor for the symptomatic treatment of Alzheimer’s disease. Because of the limited supplies from natural sources, several total syntheses have been reported to produce this drug. Galantamine has attracted both the interest of organic chemists and pharmacologists in a collaborative effort directed to design, prepare and evaluate more biologically active molecules for the treatment of Alzheimer’s disease. In this review the recent patent literature will be reviewed, showing the most important chemical and/or biochemical advances of the chemistry and biology of galantamine.
Key concepts: Galantamine, Acetylcholinesterase, Acetylcholinesterase inhibitor, Pharmacology, Donepezil, Chemistry, Alkaloid, Aché